NCT02785250 2021-06-18Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian CancerImmunoVaccine Technologies, Inc. (IMV Inc.)Phase 1/2 Unknown85 enrolled
NCT01604889 2019-03-26A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic MelanomaIncyte CorporationPhase 1/2 Terminated136 enrolled